Evolus, Inc.

NASDAQ:EOLS

Drug Manufacturers - Specialty & Generic

Healthcare
$7.07 -2.00%

-$0.14 today

Market cap
$467.95M
Beta
1.33
P/E (TTM)
-9.9
EPS (TTM)
-$0.67
52W Low $3.86High $10.20

Volume 0.80M

Average 0.86M

EOLS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Evolus, Inc.NASDAQ: EOLS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $47.36M rose 1.5% year over year, behind the +5.8% change in trailing-twelve-month gross profit. Sequentially, it fell 20.1% from the prior quarter. Over 3 fiscal years it compounded at +29.0% a year.

Context

  • Gross profit amounted to 64.9% of revenue in FY2025, down 3.6 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.5% toward the trailing-twelve-month pace of +5.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$47.36M-20.1% QoQ
Last fiscal yearDec 2025
$192.76M+5.7% YoY
LTMMar 2026
$197.81M+5.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+5.7%——
3-year CAGR+29.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
192.76M USD
Year-over-year change
+5.7%
4-year CAGR
+36.1%

Gross Profit vs competitors

How EOLS compares with its peers on the latest reported figures

No competitor Gross Profit figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue99.67M148.62M202.09M266.27M297.18M
Cost of Revenue43.53M58.84M61.56M83.97M104.41M
Gross Profit56.14M89.77M140.53M182.3M192.76M
Gross Margin56.3%60.4%69.5%68.5%64.9%
Research & Development2.06M6.74M15.43M9.17M9.58M
Selling, General & Admin112.07M141.84M164.94M198.03M220.79M
Operating Expenses100.54M155.1M189.76M216.72M230.36M
Depreciation & Amortization6.31M3.72M5.87M6.02M8.74M
EBITDA(39.06M)(53.85M)(41.81M)(25M)(22.53M)
EBITDA Margin-39.2%-36.2%-20.7%-9.4%-7.6%
Operating Income(44.41M)(65.33M)(49.23M)(34.41M)(37.6M)
Operating Margin-44.6%-44.0%-24.4%-12.9%-12.7%
Interest Income1K119K860K3.26M1.93M
Interest Expense1.4M9.1M13.83M18.74M19.69M
Other Income / Expenses(2.36M)(8.99M)(12.28M)(15.35M)(13.36M)
Income Before Tax(46.77M)(74.32M)(61.51M)(49.76M)(50.96M)
Pre-Tax Margin-46.9%-50.0%-30.4%-18.7%-17.1%
Income Tax Expense42K95K176K664K677K
Net Income(46.81M)(74.41M)(61.69M)(50.42M)(51.64M)
Net Margin-47.0%-50.1%-30.5%-18.9%-17.4%
EPS (Basic)(0.94)(1.33)(1.08)(0.81)(0.80)
EPS (Diluted)(0.94)(1.33)(1.08)(0.81)(0.80)
Weighted Avg Shares49.77M56.07M56.92M62.02M64.47M
Weighted Avg Shares (Diluted)49.77M56.07M56.92M62.02M64.47M

Evolus, Inc.

NASDAQ:EOLS

Intrinsic Alpha fair value

Locked

Current Price

$7.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.